Intraoperative indocyanine green fluorescence angiography in colorectal surgery to prevent anastomotic leakage: A single-blind phase III multicentre randomized controlled trial (FLUOCOL-01/FRENCH 21/GRECCAR 19 intergroup trial)
- PMID: 40415381
- PMCID: PMC12104609
- DOI: 10.1111/codi.70119
Intraoperative indocyanine green fluorescence angiography in colorectal surgery to prevent anastomotic leakage: A single-blind phase III multicentre randomized controlled trial (FLUOCOL-01/FRENCH 21/GRECCAR 19 intergroup trial)
Abstract
Aim: Anastomotic leak (AL) is a major problem in colorectal surgery, and its prevention is crucial for patient safety. The scientific literature shows that optimal anastomotic perfusion is essential for anastomotic healing. However, in cases of left colon or rectal cancer requiring high vessel ligation for oncological reasons, anastomotic blood supply relies mainly on the pericolic arterial arcades. Consequently, assessing anastomotic perfusion using intraoperative fluorescence angiography with indocyanine green might be relevant to reduce the risk of AL. Although evidence of its positive impact on the risk of AL is growing in the literature, most studies are descriptive prospective cohorts or retrospective comparative series with controversial findings. Furthermore, no other studies specifically address left-sided colon or high rectal tumours. FLUOCOL-1 is a large multicentre randomized controlled trial (RCT) that aims to demonstrate that assessing anastomotic perfusion using intraoperative fluorescence angiography with indocyanine green will reduce ALs in left-sided or high anterior resections with intraperitoneal anastomosis METHOD: FLUOCOL-1 is a French multicentre, single-blind, randomized, two-arm, phase III superiority clinical trial. Patients will be randomized in a 1:1 ratio to either the intervention group (FLUO+) or the control group (FLUO-). A total of 1010 patients will be randomized. The primary endpoint is the occurrence of an AL within 90 days postsurgery. AL is defined as any anastomotic dehiscence with leakage into the pelvic cavity diagnosed by imaging or surgical exploration, or any isolated pelvic organ-space infection with no evidence of fistula, as defined by the International Study Group of Rectal Cancer.
Discussion: Prevention of AL is one of the most important questions to be addressed in colorectal surgery. The FLUOCOL-1 multicentre RCT described herein aims to demonstrate that assessment of anastomotic perfusion using intraoperative fluorescence angiography with indocyanine green will reduce ALs in certain resections with intraperitoneal anastomosis.
Keywords: anastomotic leakage; colic surgery; colorectal surgery; complication; fluorescence angiography; indocyanine green; prevention.
© 2025 The Author(s). Colorectal Disease published by John Wiley & Sons Ltd on behalf of Association of Coloproctology of Great Britain and Ireland.
Conflict of interest statement
None.
The sponsor is the owner of the data and bears responsibility for data management and analysis (Dr Vernerey, Methodology and Quality of Life Unit in Oncology).
The trial can be prematurely terminated by either the coordinating investigator or the sponsor based on medical and/or administrative reasons or the results of the interim analysis. This decision will be made after mutual consultation, with reasons for discontinuation appropriately documented and notification provided to the relevant competent authorities. The sponsor is responsible for the conduct of the trial, including covering research‐related costs, promptly reporting serious adverse events and safety monitoring.
The content of this protocol is described according to the relevant items of the SPIRIT checklist (Standard Protocol Items: Recommendations for Interventional Trials) [36].
Serb supplies the ICG (Infracyanine®) used in the study free of charge. Serb is not involved in any other part of the work, including the design or analysis of the results.
Figures
References
-
- Santé publique France . Cancer du colon rectum. 2021 [cited 2021 Jul 26]. Available from: https://www.santepubliquefrance.fr/maladies‐et‐traumatismes/cancers/canc...